Abstract
Pyrrolizidine alkaloids (PAs) are naturally occurring hepatotoxins widely present in hundreds of plant species and also known to contaminate many foodstuffs, such as grain, honey, and tea. The formation of pyrrole–protein adducts via metabolic activation of PAs has been suggested as a primary trigger initiating hepatotoxicity. The present study for the first time tested the suitability of pyrrole–hemoglobin adducts as a novel and specific biomarker of PA exposure in humans. The level and elimination kinetics of pyrrole–hemoglobin adducts were systematically investigated in the blood samples of 43 PA-induced liver injury (PA-ILI) patients. The results revealed significantly higher concentrations (84.50 ± 78.38 nM) and longer persistence (~ 4 months) of pyrrole–hemoglobin adducts than that (concentration: 9.53 ± 10.72 nM; persistence: ~ 2 months) of pyrrole–plasma protein adducts, our previously developed PA exposure biomarker. Our findings confirmed that pyrrole–hemoglobin adducts with higher level and longer persistence should serve as a more applicable PA exposure biomarker for future clinical diagnosis of PA-ILI in drug/herb-induced liver injury patients.
This is a preview of subscription content, log in via an institution to check access.
References
Chojkier M (2003) Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids. J Hepatol 39(3):437–446. https://doi.org/10.1016/S0168-8278(03)00231-9
Culvenor CC, Edgar JA, Smith LW, Tweeddal HJ (1970) Dihydropyrrolizines.III. preparation and reactions of derivatives related to pyrrolizidine alkaloids. Aust J Chem 23(9):1853–1867 https://doi.org/10.1071/CH9701853
Dusemund B, Nowak N, Sommerfeld C, Lindtner O, Schafer B, Lampen A (2018) Risk assessment of pyrrolizidine alkaloids in food of plant and animal origin. Food Chem Toxicol 115:63–72. https://doi.org/10.1016/j.fct.2018.03.005
Edgar JA, Colegate SM, Boppre M, Molyneux RJ (2011) Pyrrolizidine alkaloids in food: a spectrum of potential health consequences. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 28(3):308–324. https://doi.org/10.1080/19440049.2010.547520
Edgar JA, Molyneux RJ, Colegate SM (2015) Pyrrolizidine alkaloids: potential role in the etiology of cancers, pulmonary hypertension, congenital anomalies, and liver disease. Chem Res Toxicol 28(1):4–20. https://doi.org/10.1021/tx500403t
Fennell TR, Sumner SC, Walker VE (1992) A model for the formation and removal of hemoglobin adducts. Cancer Epidemiol Biomarkers Prev 1(3):213–219
Fu PP, Xia Q, Lin G, Chou MW (2004) Pyrrolizidine alkaloids–genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev 36(1):1–55. https://doi.org/10.1081/dmr-120028426
Gao H, Ruan J, Chen J et al (2015) Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome. Drug Des Dev Ther 9:4861–4868. https://doi.org/10.2147/DDDT.S87858
Granath F, Ehrenberg L, Tornqvist M (1992) Degree of alkylation of macromolecules in vivo from variable exposure. Mutat Res 284(2):297–306. https://doi.org/10.1016/0027-5107(92)90014-s
Lin G, Wang J, Li N et al (2011) Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol 54(4):666–673. https://doi.org/10.1016/j.jhep.2010.07.031
Ma J, Xia Q, Fu PP, Lin G (2018) Pyrrole-protein adducts—a biomarker of pyrrolizidine alkaloid-induced hepatotoxicity. J Food Drug Anal 26(3):965–972. https://doi.org/10.1016/j.jfda.2018.05.005
Ma J, Ruan J, Chen X et al (2019) Pyrrole-hemoglobin adducts, a more feasible potential biomarker of pyrrolizidine alkaloid exposure. Chem Res Toxicol 32(6):1027–1039. https://doi.org/10.1021/acs.chemrestox.8b00369
Mattocks AR (1969) Dihydropyrrolizine derivatives from unsaturated pyrrolizidine alkaloids. J Chem Soc C 8:1155–1162. https://doi.org/10.1039/j39690001155
Mattocks AR (1986) Chemistry and toxicology of pyrrolizidine alkaloids. Academic Press, London Orlando
Morell A, Terry WD, Waldmann TA (1970) Metabolic properties of IgG subclasses in man. J Clin Invest 49(4):673–680. https://doi.org/10.1172/JCI106279
Morris P, O’Neill D, Tanner S (1994) Synergistic liver toxicity of copper and retrorsine in the rat. J Hepatol 21(5):735–742. https://doi.org/10.1016/s0168-8278(94)80232-7
Mulder PPJ, Lopez P, Castellari M et al (2018) Occurrence of pyrrolizidine alkaloids in animal- and plant-derived food: results of a survey across Europe. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 35(1):118–133. https://doi.org/10.1080/19440049.2017.1382726
Neumann HG, Birner G, Kowallik P, Schutze D, Zwirnerbaier I (1993) Hemoglobin adducts of N-substituted aryl compounds in exposure control and risk assessment. Environ Health Persp 99:65–69. https://doi.org/10.1289/ehp.939965
Robinson O, Want E, Coen M et al (2014) Hirmi Valley liver disease: a disease associated with exposure to pyrrolizidine alkaloids and DDT. J Hepatol 60(1):96–102. https://doi.org/10.1016/j.jhep.2013.07.039
Ruan J, Yang M, Fu PP, Ye Y, Lin G (2014) Metabolic activation of pyrrolizidine alkaloids: insights into the structural and enzymatic basis. Chem Res Toxicol 27(6):1030–1039. https://doi.org/10.1021/tx500071q
Ruan J, Gao H, Li N et al (2015) Blood pyrrole-protein adducts-a biomarker of pyrrolizidine alkaloid-induced liver injury in humans. J Environ Sci Heal C 33(4):404–421. https://doi.org/10.1080/10590501.2015.1096882
Sachse B, Hielscher J, Lampen A, Abraham K, Monien BH (2017) A hemoglobin adduct as a biomarker for the internal exposure to the rodent carcinogen furfuryl alcohol. Arch Toxicol 91(12):3843–3855. https://doi.org/10.1007/s00204-017-2005-y
Skipper PL, Tannenbaum SR (1990) Protein adducts in the molecular dosimetry of chemical carcinogens. Carcinogenesis 11(4):507–518. https://doi.org/10.1093/carcin/11.4.507
Stein TP, Leskiw MJ, Wallace HW (1978) Measurement of half-life human plasma fibrinogen. Am J Physiol 234(5):D504–D510. https://doi.org/10.1152/ajpendo.1978.234.5.E504
Tornqvist M, Fred C, Haglund J, Helleberg H, Paulsson B, Rydberg R (2002) Protein adducts: quantitative and qualitative aspects of their formation, analysis and applications. J Chromatogr B 778(1–2):279–308. https://doi.org/10.1016/s1570-0232(02)00172-1
Troester MA, Lindstrom AB, Kupper LL, Waidyanatha S, Rappaport SM (2000) Stability of hemoglobin and albumin adducts of benzene oxide and 1,4-benzoquinone after administration of benzene to F344 rats. Toxicol Sci 54(1):88–94. https://doi.org/10.1093/toxsci/54.1.88
Troester MA, Lindstrom AB, Waidyanatha S, Kupper LL, Rappaport SM (2002) Stability of hemoglobin and albumin adducts of naphthalene oxide, 1,2-naphthoquinone, and 1,4-naphthoquinone. Toxicol Sci 68(2):314–321. https://doi.org/10.1093/toxsci/68.2.314
Xia Q, Zhao Y, Lin G, Beland FA, Cai L, Fu PP (2016) Pyrrolizidine alkaloid-protein adducts: potential non-invasive biomarkers of pyrrolizidine alkaloid-induced liver toxicity and exposure. Chem Res Toxicol 29(8):1282–1292. https://doi.org/10.1021/acs.chemrestox.6b00120
Yang M, Ma J, Ruan J, Ye Y, Fu PP, Lin G (2019) Intestinal and hepatic biotransformation of pyrrolizidine alkaloid N-oxides to toxic pyrrolizidine alkaloids. Arch Toxicol 93(8):2197–2209. https://doi.org/10.1007/s00204-019-02499-2
Yee SB, Kinser S, Hill DA et al (2000) Synergistic hepatotoxicity from coexposure to bacterial endotoxin and the pyrrolizidine alkaloid monocrotaline. Toxicol Appl Pharmacol 166(3):173–185. https://doi.org/10.1006/taap.2000.8968
Zhu L, Wang Z, Wong LL et al (2018) Contamination of hepatotoxic pyrrolizidine alkaloids in retail honey in China. Food Control 85:484–494. https://doi.org/10.1016/j.foodcont.2017.10.026
Zhu L, Zhang C, Li D et al (2020) Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China. Acta Pharm Sin B. https://doi.org/10.1038/s41401-020-00553-9 ((in press))
Zhuge Y, Liu Y, Xie W et al (2019) Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. J Gastroenterol Hepatol 34(4):634–642. https://doi.org/10.1111/jgh.14612
Acknowledgements
This research was supported by Research Grants Council of Hong Kong (GRF Grants: 14111816 and 14106318) and The Chinese University of Hong Kong (Direct Grant: 4054503).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
All authors declare that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ma, J., Zhang, W., He, Y. et al. Clinical application of pyrrole–hemoglobin adducts as a biomarker of pyrrolizidine alkaloid exposure in humans. Arch Toxicol 95, 759–765 (2021). https://doi.org/10.1007/s00204-020-02947-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-020-02947-4